Pharmadrug (LMLL.F) Stock Overview
Operates as a specialty pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
LMLL.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Pharmadrug Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.017 |
| 52 Week Low | CA$0.0022 |
| Beta | 0.46 |
| 1 Month Change | 66.29% |
| 3 Month Change | 6.47% |
| 1 Year Change | 46.53% |
| 3 Year Change | -83.67% |
| 5 Year Change | -97.99% |
| Change since IPO | -99.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| LMLL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 62.6% | -0.5% | -2.3% |
| 1Y | 46.5% | 25.5% | 20.4% |
Return vs Industry: LMLL.F exceeded the US Pharmaceuticals industry which returned 26.4% over the past year.
Return vs Market: LMLL.F exceeded the US Market which returned 21.2% over the past year.
Price Volatility
| LMLL.F volatility | |
|---|---|
| LMLL.F Average Weekly Movement | 58.5% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LMLL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LMLL.F's weekly volatility (58%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | n/a | www.pharmadrug.ca |
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. It also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions.
Pharmadrug Inc. Fundamentals Summary
| LMLL.F fundamental statistics | |
|---|---|
| Market cap | US$984.75k |
| Earnings (TTM) | -US$178.91k |
| Revenue (TTM) | n/a |
Is LMLL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMLL.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$243.85k |
| Earnings | -CA$243.85k |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0018 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -98.7% |
How did LMLL.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 11:00 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmadrug Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.